Name

PharmaLegacy Laboratories

Legal name

PharmaLegacy Research LLC

Website

https://pharmalegacy.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Preclinical Contract Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical Laboratories (621511)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)

akta.pro secondary industries

Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC), Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD), Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

Keywords

• Preclinical contract research
• In vivo pharmacology services
• Drug metabolism pharmacokinetics
• Animal model studies
• Preclinical CRO services

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Contract Research Services: PharmaLegacy generates revenue through providing preclinical contract research services to pharmaceutical, biotechnology, medical device, and diagnostics companies. Services include in vitro efficacy testing, in vivo pharmacology studies, DMPK, toxicology, PK/PD, and histopathology. Revenue is project-based with contracts for specific studies or comprehensive preclinical programs.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

PharmaLegacy Laboratories is a preclinical contract research organization (CRO) that provides in vitro and in vivo pharmacology services to pharmaceutical, biotechnology, medical device, and diagnostics companies. Its offerings span over 1,500 validated animal models across more than 100 indications, including oncology/immuno-oncology, inflammation/autoimmunity, neuroscience, metabolic, hepatic/renal, cardiovascular, pulmonary, bone/orthopedics, and ophthalmology research. The company supports IND-enabling studies through integrated DMPK, toxicology, PK/PD, histopathology, biomarker, and medical device testing services from facilities in Shanghai and San Diego.

Product overview

PharmaLegacy Laboratories is a preclinical Contract Research Organization (CRO) founded in 2008, providing integrated in vitro and in vivo pharmacology studies. The company operates a platform of laboratory services organized around therapeutic focus areas (Oncology/Immuno-Oncology, Inflammation/Autoimmunity, Neuroscience, Metabolic Diseases, Cardiovascular, etc.) supported by core technical services including In Vitro Efficacy and Safety Testing, DMPK (ADME, PK, Toxicology, Bioanalysis), Non-Human Primate Studies, Histopathology, Biomarker Discovery, and Medical Device Testing. The company has over 1,500 validated animal models across 100+ indications, 380,000 square feet of facility space, capacity for 30,000+ animals, and has supported over 400 IND applications. Following the September 2024 acquisition of BTS Research (adding GLP toxicology services), the company now has expanded laboratory operations in North America (San Diego) alongside its Shanghai headquarters.

Differentiator

Problem solved

Functional benefit

Brands

• BTS Research: A San Diego-based preclinical CRO acquired by PharmaLegacy in September 2024, providing GLP and non-GLP biological services across pharmaceutical, biopharmaceutical, biotech, academic research, medical device, and diagnostic industries.

Products and services

• In Vitro Efficacy and Safety Testing Services Comprehensive in vitro laboratory testing services including kinase/enzyme assays, GPCR assays, cell-based cytotoxicity and immune modulatory assays, ADC evaluation, vaccine evaluation, flow cytometry/FACS analysis, safety assays, and biomarkers/pharmacodynamics analysis. Designed for pharmaceutical and biotechnology R&D teams.
• DMPK (Drug Metabolism and Pharmacokinetics) Services Integrated DMPK services covering ADME (Absorption, Distribution, Metabolism, Excretion), pharmacokinetics, toxicology, and bioanalysis for drug discovery support. Compliant with FDA, EMA, and NMPA regulations with FDA Part 11 compliance.
• In Vivo Animal Model Studies Preclinical in vivo pharmacology studies across over 1,500 validated animal models spanning 100+ indications in therapeutic areas including oncology, inflammation, autoimmunity, neuroscience, metabolic diseases, and more. Most models available immediately with studies starting in under two weeks.
• Non-Human Primate (NHP) Studies Specialized non-human primate studies using cynomolgus monkeys for inflammation, immune and autoimmune diseases, hematology and thrombosis, metabolic disease models, ophthalmology, and orthopedics research. NHPs are farm-raised for research use with verified provenance.
• Histopathology Services Histopathology and histomorphometry analysis services for preclinical studies including cancer pathology, inflammatory pathology, toxicological pathology, and specialized tissue implant analysis.
• Biomarker Discovery and Detection Biomarker detection services including in vitro immunization, cytokines profiling, molecular biology, and Western blot analysis for preclinical drug development programs.
• Medical Device Testing Preclinical testing services for medical devices including cardiovascular devices, cerebrovascular devices, bone/dental devices, and doctor-operated devices.
• Oncology / Immuno-Oncology Platform Comprehensive oncology research services including humanized mouse models (HuCD34+ and HuPBMC), syngeneic mouse models, xenograft mouse models, nude rat models, ex-vivo tumor studies, bone metastasis models, human cancer cell panel, and ADC characterization and evaluation.
• Inflammation, Immunity and Autoimmunity Models Animal models for arthritis, allergy/hypersensitivity, colitis, neuroinflammation, uveitis/conjunctivitis, pneumonitis, psoriasis, systemic lupus erythematosus, graft-versus-host disease, sepsis, and general inflammation studies.
• Neuroscience Disease Models Neurodegenerative disease models including Alzheimer's, Parkinson's, ALS, Huntington's, spinal muscular atrophy, Rett syndrome, and aging studies, plus neuropsychiatric disease models for depression, anxiety, schizophrenia, and addiction.
• Ophthalmology Disease Models Comprehensive ocular disease models including dry AMD, wet AMD, glaucoma, diabetic retinopathy, dry eye, myopia/presbyopia, ocular gene therapy, and retinal disease models.
• GLP Toxicology Services (BTS Research) GLP and non-GLP biological services for pharmaceutical, biopharmaceutical, biotech, academic research, medical device, and diagnostic industries, added through the BTS Research acquisition.

Quantifiable outcome

• 400+ IND applications supported for clients
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Catawba ResearchcoreStrategic or Co-development Partner · 22 October 2024Strategic partnership announced October 2024 enables end-to-end drug development solutions combining PharmaLegacy's preclinical expertise with Catawba Research's clinical trial management capabilities. The collaboration provides Catawba Research with new access to China and expanded APAC capabilities while allowing PharmaLegacy to offer comprehensive preclinical and clinical research services.
• BTS ResearchcoreStrategic or Co-development Partner · 1 September 2024PharmaLegacy acquired BTS Research, a San Diego-based preclinical CRO, in September 2024. The acquisition expands PharmaLegacy's laboratory footprint in North America, adds GLP toxicology services to its offerings, and strengthens support for global biopharmaceutical clients. BTS Research has roots dating back to 2001.
• FrontageminorStrategic or Co-development PartnerFrontage is a CRO providing integrated, scientifically-driven research, analytical and development services throughout the drug discovery and development process. Partnership enables collaboration on laboratory services supporting drug discovery and development including DMPK, safety and toxicology, and bioanalytical services.
• TigermedminorStrategic or Co-development PartnerHangzhou Tigermed Consulting Co., Ltd (stock symbol: 300347) is a leading CRO in China providing full clinical trial services since 2004. Partnership enables collaboration across clinical trials with operations in 33 subsidiaries, 63 offices across China, and 12 overseas offices globally.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Labcorp Drug Development (formerly Covance): Diversified clinical and preclinical CRO serving global biopharma. Competes with PharmaLegacy on preclinical pharmacology, safety, and integrated discovery-to-clinical packages, with deeper US footprint and bundled service offerings.
• Eurofins Scientific: Global testing services group with growing preclinical CRO footprint via acquisitions. Provides overlapping in vitro ADME, bioanalytical, and safety testing services to the same biopharma customers as PharmaLegacy.
• Charles River Laboratories: Global leader in preclinical CRO services including animal models, safety assessment, and DMPK. Sets pricing and quality benchmarks in the same preclinical categories where PharmaLegacy competes; broader and better-capitalized.

Direct peers

• Shanghai Medicilon: China-based preclinical CRO providing in vivo and in vitro pharmacology, DMPK, and IND-enabling toxicology. Most similar China-domiciled peer to PharmaLegacy in scale and service breadth.
• Inotiv: US-based preclinical CRO offering in vivo toxicology, animal models, and discovery research services. Comparable scale and service mix in GLP toxicology and pharmacology, with a primarily North American sponsor base.
• Crown Bioscience (JSR Life Sciences): Global preclinical CRO specializing in oncology and immuno-oncology animal models, including humanized mouse and syngeneic/xenograft platforms. Directly comparable to PharmaLegacy's oncology and I-O indication library.
• Wuxi AppTec: China-headquartered global CRO offering preclinical in vitro and in vivo services, DMPK, and toxicology at very large scale. Closest direct peer to PharmaLegacy's Shanghai-based preclinical model and the canonical Chinese preclinical CRO benchmark.
• Frontage Holdings: US-listed CRO with Chinese roots providing bioanalytical, DMPK, and preclinical services. Already named as a PharmaLegacy partner, it competes for many of the same biopharma sponsors in DMPK and safety assessment.
• Pharmaron: China-origin, global CRO providing preclinical in vitro/in vivo pharmacology, DMPK, safety assessment, and integrated drug discovery services. Highly comparable business model and customer base to PharmaLegacy.

Emerging players

• Bionova Scientific: US-based preclinical CRO with focus on biologics, gene therapy, and vaccine testing. Smaller and more focused than PharmaLegacy but competes for biotech preclinical outsourcing dollars in overlapping therapeutic areas.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/pharmalegacy

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PharmaLegacy Laboratories